Literature DB >> 2939795

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

L J Eron, L Harvey, D L Hixon, D M Poretz.   

Abstract

Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli. The types of infections treated included those of skin or skin structure, bone, urinary tract, and respiratory tract. In 83% of P. aeruginosa infections, a favorable clinical outcome occurred, compared with 85% for all infections. Failure to achieve a cure correlated with the emergence of resistant P. aeruginosa and Acinetobacter calcoaceticus strains in four instances and superinfection with Candida (two cases) and Streptococcus (two cases) species. Therapy was discontinued in three patients because of the development of nausea. Ciprofloxacin appears to be safe and effective in the therapy of infections caused by resistant gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2939795      PMCID: PMC180237          DOI: 10.1128/AAC.28.2.308

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.

Authors:  G B Calandra; M Hesney; C Grad
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

2.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 3.  Tobramycin sulfate: a summary of worldwide experience from clinical trials.

Authors:  C L Bendush; R Weber
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

4.  Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.

Authors:  G L Simon; D R Snydman; F P Tally; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

5.  Ceftazidime in patients with Pseudomonas infections.

Authors:  L J Eron; C H Park; D L Hixon; R I Goldenberg; D M Poretz
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

6.  Piperacillin therapy for Pseudomonas infections.

Authors:  L J Eron; R I Goldenberg; D M Poretz; C H Park
Journal:  South Med J       Date:  1983-07       Impact factor: 0.954

7.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.

Authors:  N Clumeck; Y Van Laethem; B Gordts; N Jaspar; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.

Authors:  T F Murphy; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

10.  Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Authors:  R Platt; S L Ehrlich; J Afarian; T F O'Brien; J E Pennington; E H Kass
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

  10 in total
  23 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

3.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.

Authors:  M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

Review 5.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

6.  Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.

Authors:  H Lode; R Wiley; G Höffken; J Wagner; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

7.  Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity.

Authors:  U B Schaad; J Wedgwood-Krucko
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

8.  Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.

Authors:  C R Marchbanks; J R McKiel; D H Gilbert; N J Robillard; B Painter; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

10.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.